Difference between revisions of "Sorafenib (Nexavar)"
Jump to navigation
Jump to search
(updated content) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf Sorafenib (Nexavar) package insert]</ref><ref>[ | + | Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.<ref name="insert">[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf Sorafenib (Nexavar) package insert]</ref><ref>[[Media:Sorafenib.pdf | Sorafenib (Nexavar) package insert (locally hosted backup)]]</ref><ref>[http://www.nexavar.com Nexavar manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 14: | Line 14: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf#page= | + | *[http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf#page=26 Sorafenib (Nexavar) package insert PDF pages 26-30]<ref name="insert"></ref> |
| − | *[http://chemocare.com/ | + | *[http://www.chemocare.com/chemotherapy/drug-info/Sorafenib.aspx Sorafenib (Nexavar) patient drug information (Chemocare)]<ref>[http://www.chemocare.com/chemotherapy/drug-info/Sorafenib.aspx Sorafenib (Nexavar) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/sorafenib-patient-drug-information Sorafenib (Nexavar) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *12/20/2005: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108538.htm FDA approved] "for the treatment of patients with advanced renal cell carcinoma (RCC)." | ||
| + | *11/16/2007: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129234.htm FDA approved] "for the treatment of patients with unresectable hepatocellular carcinoma (HCC)." | ||
| + | *11/22/2013: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm FDA approved] "for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment" | ||
| + | |||
| + | ==Also known as== | ||
| + | Sorafenib Tosilate | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Kinase inhibitors]] | ||
| + | [[Category:BRAF inhibitors]] | ||
| + | [[Category:VEGF inhibitors]] | ||
| + | [[Category:PDGFR inhibitors]] | ||
| + | |||
| + | [[Category:Acute myeloid leukemia medications]] | ||
| + | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Melanoma medications]] | ||
| + | [[Category:Renal cancer medications]] | ||
| + | [[Category:Thyroid cancer medications]] | ||
Revision as of 03:32, 16 December 2013
General information
Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: CRAF, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Sorafenib (Nexavar) package insert PDF pages 26-30[1]
- Sorafenib (Nexavar) patient drug information (Chemocare)[4]
- Sorafenib (Nexavar) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/20/2005: FDA approved "for the treatment of patients with advanced renal cell carcinoma (RCC)."
- 11/16/2007: FDA approved "for the treatment of patients with unresectable hepatocellular carcinoma (HCC)."
- 11/22/2013: FDA approved "for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment"
Also known as
Sorafenib Tosilate